Select Publications

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.

Jones S et al. Extended follow-up and analysis by age of the US Oncology adjuvant trial 9735: Docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium 2007;Abstract 12.

Lin NU et al. Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer — An updated analysis from EGF105084. San Antonio Breast Cancer Symposium 2007;Abstract 6076.

Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract

Peto R, on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women-Preliminary results. San Antonio Breast Cancer Symposium 2007;Abstract 48.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Home · Search

EDITOR'S NOTE
San Antonio adventure, 2007
Neil Love, MD
- Select publications

INTERVIEWS
Stephen E Jones, MD
- Select publications

Sir Richard Peto, FRS
- Select publications

Kathy S Albain, MD
- Select publications

Roundtable Discussion
- Select publications

Joyce O’Shaughnessy, MD
- Select publications

Nancy U Lin, MD
- Select publications

Breast Cancer Update:
A CME Audio Series and Activity

Editor's Office

Faculty Disclosures